10 January 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Pembrolizumab (Keytruda)
  
• Atezolizumab (Tecentriq)
  
• Idaracizumab (Praxbind)
  
• Ranibizumab (Lucentis)
  
• Carfilzomib (Kyprolis)
  
• Ixazomnib citrate (Ninlaro)
  
• Daratumumab (Darzalex)
  
• Sarilumab (Kevzara)
  

Read TC agenda